Dissemin is shutting down on January 1st, 2025

Published in

Elsevier, Journal of Neuroimmunology, 1-2(269), p. 87-89, 2014

DOI: 10.1016/j.jneuroim.2014.02.004

Links

Tools

Export citation

Search in Google Scholar

CSF levels of YKL-40 are increased in MS and decrease with immunosuppressive treatment

Journal article published in 2014 by Clas Malmeström, Markus Axelsson, Jan Lycke ORCID, Henrik Zetterberg, Kaj Blennow, Bob Olsson
This paper was not found in any repository, but could be made available legally by the author.
This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

The role of glial cells during different phases of multiple sclerosis (MS) is unclear. To monitor glial activation we analyzed the biomarkers YKL-40 and sCD14 in cerebrospinal fluid (CSF) from MS patients during different disease phases and in response to immunosuppressive treatment. CSF levels of YKL-40 were increased in MS during relapse, remission and secondary progression compared with healthy controls. Furthermore, YKL-40 levels in CSF decreased by mitoxantrone and natalizumab treatment. No differences were observed in CSF levels of sCD14. Thus, we can infer that glial activation is present in all MS phases and decreases by immunosuppressive treatment. © 2014 Elsevier B.V.